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CS-1  Translational science in drug 
discovery research: Challenges and 
possible solutions
Katsumi Sudoh
Translational Sci. Res. Lab., Drug Discovery Res., Astellas Pharma Inc.
Translational Science (TS) has been of more importance to 
bridge basic research in the preclinical stage and patient 
care in the clinical stage. From drug discovery research 
point of view, it can enhance our understanding and 
confidence in targets, bringing potential compounds and 
biologics up to Proof of Concept earlier. There are at least 
three key tools/methods for TS, biomarkers, bio-imaging, 
and pharmacokinetics-pharmacodynamics analysis and 
modeling  & simulation (PK-PD M&S). Biomarkers are 
most potential tools, which are identiÀ ed for understanding 
mechanism, pharmacology, efÀ cacy and patient stratiÀ cation 
etc. Bio-imaging is a tool/method for TS to investigate 
pharmacokinetics, pharmacodynamics and efficacy 
especially in target organs with more minimally invasive. 
PK-PD M&S is also a potential tool/method to estimate 
clinical dosing regimen. These tools/methods have been tried 
to be adopted in all research programs to accelerate and 
promote TS to effectively bridge drug discovery research and 
clinical development, but there have been various challenges 
need to be resolved as early as possible. In this presentation, 
based on our experiences, we will provide challenges and 
possible solutions on TS from preclinical point of view.
CS-3  Pharmacodynamics 
biomarkers: Applications and 
considerations in clinical development
Seiji Mito, Masaki Sakai, Masayuki Suzuki
Clinical Pharmacology Dept. Development Dev. Mitsubishi Tanabe Pharma 
Corporation
Pharmacodynamics (PD) biomarkers are used for seeking 
drug exposure at the site of action, drug binding to the 
target, drug effect on the downstream pathway and linkage 
to the clinical endpoint. Especially, PD biomarkers are 
necessary to demonstrate mode of action (MOA) of drug. 
In addition, PD biomarkers can help to determine effective 
dose and contribute to dose selection for subsequent clinical 
studies. In implementation of PD biomarkers in clinical 
studies, we face various challenges such as biomarker 
qualiÀ cation and method validation for biomarker analysis. 
Biomarkers can be classified by validity based on their 
clinical evidence. Regarding method validation, “fit-for-
purpose” approach is generally accepted. For exploratory 
use, less-rigorous validation would be acceptable. In 
contrast, for critical decision making, rigorous validation 
should be conducted. Appropriate cooperation of clinical 
team and non-clinical team and reconstruction of 
biomarker strategies after change of indication would be 
also challenges. I would like to introduce our processes on 
selection of PD biomarkers in Phase II study in subjects 
with an immunological disease.SCS-2  Translational science in drug 
development: Challenges and possible 
solutions
Susumu Nakade
Translational Medicine Center, Ono Pharmaceutical Co., Ltd.
In the late 20th century, the entire pharmaceutical industry 
grew signiÀ cantly due to successive launch of blockbusters. 
However, productivity in drug development has been 
gradually decreased.  From the 21st century, the hurdle 
of new drug approval became even higher. In addition, 
the market of developed countries has reached the ceiling 
because of the price control measures taken worldwide. 
Due to such factors, pharmaceutical companies are forced 
to change in order to improve productivity. In previous 
drug development, time and money were invested from 
the initial clinical development. However, less than 10 % 
of the drugs for which phase 1 study has been conducted 
gain approval. Therefore, pharmaceutical companies 
have stopped assuming success, and are shifting to the 
direction to judge the effectiveness in human as quickly 
and inexpensively as possible. The methodology to enable 
this has become important, and I believe that translational 
science is the answer. In academia, translational science is 
often expressed as “from bench to bedside”. However, are 
efforts in translational science actually being progressed in 
pharmaceutical companies? In this presentation, I would 
like to introduce the world’s trend in translational science.26
